MedTrace Logo

Fosmidomycin With Clindamycin or With Clindamycin Plus Artesunate

NCT01002183 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2011-09-27

No results posted yet for this study

Summary

The aim of this study is to evaluate the role of clindamycin and artesunate as possible combination partners for fosmidomycin to protect it from its susceptibility to recrudescent infections when used as monotherapy for acute Plasmodium falciparum malaria while retaining its excellent safety profile

Conditions

Interventions

DRUG

Fosmidomycin

450 mg capsules, every 12 hrs for 3 days

Sponsors & Collaborators

  • Mahidol University

    collaborator OTHER

  • Thammasat University

    collaborator OTHER

  • Jomaa Pharma GmbH

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
15 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • Thailand

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01002183 on ClinicalTrials.gov